Trial Profile
Open Label, Multicenter, Prospective Phase II Study to Investigate the Efficacy and Safety of Trastuzumab Biosimilar (Herzuma) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer Who Progressed After 2 or More HER-2 Directed Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 13 Sep 2022 Results assessing genomic analysis of plasma cell-free DNA in patients with heavily pretreated HER-2+ metastatic breast cancer, presented at the 47th European Society for Medical Oncology Congress
- 10 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2018 New trial record